75,740 Shares in Metagenomi, Inc. (NASDAQ:MGX) Bought by Fortitude Advisory Group L.L.C.

Fortitude Advisory Group L.L.C. bought a new stake in shares of Metagenomi, Inc. (NASDAQ:MGX) in the 4th quarter, HoldingsChannel.com reports. The firm bought 75,740 shares of the company’s stock, valued at approximately $273,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. BNP Paribas Financial Markets lifted its stake in Metagenomi by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock valued at $28,000 after buying an additional 7,256 shares in the last quarter. Verition Fund Management LLC acquired a new stake in shares of Metagenomi during the third quarter valued at approximately $82,000. Geode Capital Management LLC boosted its stake in Metagenomi by 105.8% in the 3rd quarter. Geode Capital Management LLC now owns 338,031 shares of the company’s stock worth $734,000 after purchasing an additional 173,796 shares during the period. Jacobs Levy Equity Management Inc. grew its position in Metagenomi by 209.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company’s stock worth $296,000 after purchasing an additional 92,468 shares in the last quarter. Finally, Green Alpha Advisors LLC acquired a new stake in Metagenomi during the 3rd quarter valued at $69,000.

Wall Street Analyst Weigh In

MGX has been the topic of a number of research analyst reports. HC Wainwright lifted their price target on Metagenomi from $7.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, December 10th. Chardan Capital reiterated a “buy” rating and issued a $15.00 target price on shares of Metagenomi in a report on Wednesday, November 20th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Metagenomi presently has an average rating of “Moderate Buy” and an average target price of $16.67.

Metagenomi Price Performance

MGX opened at $2.77 on Tuesday. The stock has a fifty day moving average price of $2.95 and a 200 day moving average price of $2.89. Metagenomi, Inc. has a 1 year low of $1.61 and a 1 year high of $12.74.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.